Bifunctional Proteolysis Targeting Chimeric Compounds for Protein Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for diseases such as hyperplasias and cancers, particularly multiple myeloma, face challenges in specificity and non-specific effects due to the difficulty in targeting and modulating certain protein classes, including transcription factors, with existing small-molecule therapeutic agents.
Innovation Solution
Development of bifunctional or proteolysis targeting chimeric (PROTAC) compounds that comprise an E3 ubiquitin ligase binding moiety and a protein/polypeptide targeting moiety, allowing for the recruitment of endogenous proteins to an E3 ubiquitin ligase for degradation, thereby modulating targeted ubiquitination and inhibition across a broad range of protein classes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If small molecule drugs are used to target proteins, then they can bind to enzymes or receptors in tight pockets, but they cannot effectively target protein-protein interactions due to large contact surfaces and shallow interfaces
Solution Approach 1:
The bifunctional compound is divided into two distinct functional moieties: an E3 ligase binding moiety that targets the ubiquitin ligase, and a protein of interest binding moiety that targets the disease-associated protein. This segmentation allows each moiety to independently bind its target, overcoming the limitation of small molecules unable to effectively target large protein-protein interaction surfaces.
Solution Approach 2:
The bifunctional compound acts as an intermediary molecule that bridges the E3 ligase and the protein of interest. By containing both binding moieties in a single molecule, it mediates the recruitment of the protein of interest to the E3 ligase, enabling targeted ubiquitination without requiring the protein to directly bind the small molecule.
2Reliability
If existing small-molecule therapeutic agents are used, then they can treat diseases, but they produce non-specific effects and cannot target certain protein classes like transcription factors
Solution Approach 1:
The bifunctional compound exhibits local quality by having different functional regions with specific binding properties. The E3 ligase binding moiety specifically recognizes and binds to the E3 ligase, while the protein of interest binding moiety specifically recognizes and binds to the target protein. This localized specificity ensures that only the intended protein targets are affected, eliminating non-specific therapeutic effects.
Solution Approach 2:
The invention changes the fundamental parameter of drug action from direct enzyme inhibition to targeted protein degradation via ubiquitination. By altering the mechanism of action from blocking active sites to recruiting proteasomal degradation, the therapy achieves high specificity for target proteins while avoiding off-target effects on non-target proteins.
3Adaptability or versatility
If bifunctional PROTAC compounds are developed to target multiple protein classes, then a broad range of pharmacological activities becomes possible, but the complexity of the compounds increases
Solution Approach 1:
The bifunctional compound design enables universality by creating a platform that can target multiple different protein classes. By maintaining a conserved E3 ligase binding moiety and varying only the protein of interest binding moiety, the same basic structure can be adapted to target transcription factors, kinases, and other previously undruggable proteins, achieving broad pharmacological activity across diverse protein classes.
Data Source
AI summary
The description relates to Inhibitors of Apoptosis Proteins (IAPs) binding compounds, including bifunctional compounds comprising the same, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the description provides compounds, which contain on one end a ligand which binds to the IAP E3 ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. Compounds can be synthesized that exhibit a broad range of pharmacological activities consistent with the degradation/inhibition of targeted polypeptides of nearly any type.